Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit

Critical Care Medicine

Volumn 24, Issue 11, 1996, Pages 1775-1781

  Friedland, Jon S ^a   Porter, Joanna C ^a   Daryanani, Sunil ^a   Bland, J Martin ^a   Screaton, Nicholas J ^a   Vesely, Martin J J ^a   Griffin, George E ^a   Bennett, E David ^a   Remick, Daniel G ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

critical illness; cytokines; intensive care; interleukin 6; interleukin 1; interleukin 8; prognosis; systemic inflammatory response syndrome (SIRS); tumor necrosis factor

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CRITICAL ILLNESS; DIAGNOSTIC VALUE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

EID: 0029825840     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199611000-00003     Document Type: Article

References (37)

1. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474
2. Waage A, Haalstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i:355-357
3. Grau GE, Taylor TE, Molyneux ME, et al: Tumour necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989; 320: 1586-1591
4. Dinarello CA, Wolff SM: The role of interleukin-1 in disease. N Engl J Med 1993; 328:106-113
5. Calandra T, Baumgartner J-D, Grau GE, et al: Prognostic value of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock. J Infect Dis 1990; 161:982-987
6. Damas P, Reuter A, Gysen P, et al: Tumor necrosis factor and interleukin-1 serum levels during sepsis in humans. Crit Care Med 1989; 17:975-978
7. Waage A, Brandtzaeg P, Halstensen A, et al: The complex pattern of cytokines in serum from patients with meningococcal septic shock: Association between interleukin 6, interleukin 1 and fatal outcome. J Exp Med 1990; 169:333-338
8. Marano MA, Fong Y, Moldawer LL, et al: Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990; 170:32-38
9. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 1993; 119: 771-778
10. Rabinovici R, John R, Esser KM, et al: Serum tumor necrosis factor-alpha profile in trauma patients. J Trauma 1993; 35:698-702
11. Miller MD, Krangel MS: Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992; 12: 17-46
12. Marty C, Misset B, Tamion F, et al: Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin. Crit Care Med 1994; 22:673-679
13. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-1655
14. Knaus WA, Wagner DP, Draper EA, et al: The APACHE III prognostic system: Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-1636
15. Bone RC: A critical evaluation of new agents for the treatment of sepsis. JAMA 1991; 266:1686-1691
16. Dinarello CA, Gelfand JA, Wolff SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269: 1829-1835
17. Wherry JC, Pennington JE, Wenzel RP: Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med 1993; 21:S436-S440
18. Fisher CJ, Dhainaut J-FA, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with the sepsis syndrome. JAMA 1994; 271:1836-1843
19. Wherry J, Wenzel R, Wunderink R, et al: Monoclonal antibody to human tumor necrosis factor (TNF MAb): Multicentre safety and efficacy study in patients with the sepsis syndrome. New Orleans, LA, American Society for Microbiology, 1993, pp 246
20. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
21. Friedland JS, Suputtamongkol Y, Remick DG, et al: Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect Immunol 1992; 60:2402-2408
22. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986; 95:99-105
23. Aarden LA, De Groot DR, Schaap OL, et al: Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987; 17:1411-1416
24. Ulich TR, Guo K, Remick DG, et al: Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J Immunol 1991; 146:2316-2323
25. DeForge LE, Remick DG: Sandwich ELISA for detection of picogram quantities of Interleukin-8. Immunol Invest 1991; 20:89-97
26. Hack CE, Hart M, van Schijndel RJMS, et al: Interleukin-8 in sepsis: Relation to shock and inflammatory mediators. Infect Immunol 1992; 60:2835-2842
27. Beutler B, Grau GE: Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993; 21: S423-S435
28. Strieter RM, Kunkel SL, Bone RC: Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 1993; 21:S447-S463
29. van Zee KJ, Kohno T, Fischer E, et al: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845-4849
30. Rodriguez JL, Miller CG, DeForge LE, et al: Local production of interleukin-8 is associated with nosocomial pneumonia. J Trauma 1992; 33:74-82
31. Suter PM, Suter S, Girardin E, et al: High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145: 1016-1022
32. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during sepsis in human: IL-6 as a marker of severity. Ann Surg 1992; 215:356-362
33. Fisher CJ, Opal SM, Dhainaut J-F, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
34. Offner F, Philippe J, Vogelaers D, et al: Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990; 116: 100-105
35. van Dissell JT, Groeneveld PHP, Maes B, et al: Nitric oxide: A predictor of morbidity in postoperative patients. Lancet 1994; 343:1579-1580
36. Pinsky MR, Vincent J-L, Deviere J, et al: Serum cytokine levels in human septic shock: Relation to multiple system organ failure and mortality. Chest 1993; 103:565-575
37. Rangel-Frusto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-123